Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03068468
Other study ID # 251PP301
Secondary ID 2016-002554-21CN
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 1, 2017
Est. completion date February 7, 2020

Study information

Verified date November 2020
Source Biogen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Primary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) at Week 52 and to assess the safety and tolerability of BIIB092, relative to placebo, by measuring the frequency of deaths, SAEs, AEs leading to discontinuation, and Grade 3 & 4 laboratory abnormalities. The Secondary objective of the study is to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Movement Disorder Society (MDS)-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by the Clinical Global Impression of Change (CGI-C) at Week 52, to evaluate the efficacy of BIIB092, compared to placebo, as measured by a change in baseline in the Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) at Week 52 and to assess the impact of BIIB092 on quality of life, relative to placebo, as measured by change from baseline on the Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) at Week 52.


Description:

This study, previously posted by Bristol-Myers Squibb, has transitioned to Biogen under a licensing agreement.


Recruitment information / eligibility

Status Terminated
Enrollment 490
Est. completion date February 7, 2020
Est. primary completion date September 6, 2019
Accepts healthy volunteers No
Gender All
Age group 41 Years to 86 Years
Eligibility Key Inclusion Criteria: - Participants with probable or possible PSP - Able to ambulate independently or with assistance - Able to tolerate MRI - Have reliable caregiver to accompany participant to all study visits - Score greater or equal to 20 on the Mini Mental State Exam (MMSE) at screening - Participant must reside outside a skilled nursing facility or dementia care facility at the time of screening and admission to such a facility must not be planned Key Exclusion Criteria: - Presence of other significant neurological or psychiatric disorders - Diagnosis of amyotrophic lateral sclerosis (ALS) or other motor neuron disease - History of early, prominent rapid eye movement (REM) sleep behavior disorder - History of or screening brain MRI scan indicative of significant abnormality - Known history of serum or plasma progranulin level less than one standard deviation below the normal patient mean for the laboratory performing the assay NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BIIB092
BIIB092 intravenous infusion on specified days
Placebo
Placebo intravenous infusion on specified days

Locations

Country Name City State
Australia Research Site North Melbourne Victoria
Austria Research Site Innsbruck Tirol
Austria Research Site Vienna
Canada Research Site London Ontario
Canada Research Site Ottawa Ontario
Canada Research Site Toronto Ontario
France Research Site Bordeaux
France Research Site Lille
France Research Site Marseille
France Research Site Nimes
France Research Site Paris
France Research Site Rennes
France Research Site Toulouse
Germany Research Site Beelitz-Heilstatten
Germany Research Site Bochum
Germany Research Site Bonn
Germany Research Site Dresden Sachsen
Germany Research Site Dusseldorf North Rhine-Westphalia
Germany Research Site Essen
Germany Research Site Kassel
Germany Research Site Kiel Schleswig-Holstein
Germany Research Site Luebeck Schleswig-Holstein
Germany Research Site Marburg Hessen
Germany Research Site Munich Bavaria
Germany Research Site Rostock Mecklenburg-Western-Pommerania
Germany Research Site Ulm
Greece Research Site Athens Marousi
Italy Research Site Pisa
Italy Research Site Salerno Campania
Italy Research Site Venice Lido
Japan Research Site Kamagaya Chiba
Japan Research Site Kodaira Tokyo
Japan Research Site Nagoya Aichi
Japan Research Site Sagamihara Kanagawa
Japan Research Site Sapporo Hokkaido
Japan Research Site Shizuoka
Japan Research Site Yonago Tottori
Korea, Republic of Research Site Seoul
Russian Federation Research Site Krasnoyarsk
Russian Federation Research Site Moscow
Spain Research Site Barakaldo Vizcaya
Spain Research Site Barcelona
Spain Research Site Madrid
Spain Research Site Pamplona Navarra
Spain Research Site Sevilla
Spain Research Site Valencia
United Kingdom Research Site Brighton East Sussex
United Kingdom Research Site Cambridge Cambridgeshire
United Kingdom Research Site Liverpool Merseyside
United Kingdom Research Site London
United Kingdom Research Site Newcastle Upon Tyne Tyne And Wear
United Kingdom Research Site Newport Wales
United Kingdom Research Site Southampton Hampshire
United States Research Site Albany New York
United States Research Site Baltimore Maryland
United States Research Site Baltimore Maryland
United States Research Site Boca Raton Florida
United States Research Site Boston Massachusetts
United States Research Site Burlington Massachusetts
United States Research Site Charleston South Carolina
United States Research Site Charlottesville Virginia
United States Research Name Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Chicago Illinois
United States Research Site Dallas Texas
United States Research Site Farmington Hills Michigan
United States Research Site Fountain Valley California
United States Research Site Gainesville Florida
United States Research Site Hershey Pennsylvania
United States Research Site Indianapolis Indiana
United States Research Site Kansas City Kansas
United States Research Site La Jolla California
United States Research Site Los Angeles California
United States Research Site Minneapolis Minnesota
United States Research Site New Brunswick New Jersey
United States Research Site New Orleans Louisiana
United States Research Site New York New York
United States Research Site New York New York
United States Research Site New York New York
United States Research Site Philadelphia Pennsylvania
United States Research Site Phoenix Arizona
United States Research Site San Francisco California
United States Research Site Scottsdale Arizona
United States Research Site Seattle Washington
United States Research Site Sun City Arizona
United States Research Site Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Canada,  France,  Germany,  Greece,  Italy,  Japan,  Korea, Republic of,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Progressive Supranuclear Palsy Rating Scale (PSPRS) at Week 52 The PSPRS is a quantitative measure of disability in participants with PSP. The PSPRS comprises 28 items in 6 areas. Six items are rated on a 3-point scale (0-2) and 22 are rated on a 5-point scale (0-4). The 6 areas are the History/Daily Activities, Mentation, Bulbar, Ocular Motor, Limb Motor, and Gait. The 28-item PSPRS total score ranges from 0 (normal) to 100. Fifteen items are selected to form a 15-item PSPRS and three domains are identified: Gait/Limb function, Ocular Motor, and Bulbar. The total 15-item PSPRS score ranges from 0 (normal) to 52. A positive change from baseline indicates worsening. Baseline, Week 52
Primary Percentage of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) and Adverse Events (AEs) Leading to Discontinuation of Drug AEs: any sign, symptom, or diagnosis/disease that is unfavorable or unintended, that is new, or if pre-existing, worsens in participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. SAEs: an event that results in death; an event that, in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); an outcome that results in a congenital anomaly/birth defect diagnosed in a child of a participant; an event that requires or prolongs inpatient hospitalization; an event that results in persistent or significant disability/incapacity. up to 52 weeks
Secondary Change From Baseline in Movement Disorder Society (MDS)-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II at Week 52 The MDS-UPRDRS Part 2 includes 13 items assessing motor aspects of experiences of daily living (M-EDL) these include speech, saliva and drooling, chewing and swallowing, handwriting, doing hobbies and other activities, eating tasks, tremor, dressing, hygiene, turning in bed, getting out of bed, walking and balance, and freezing. All items have 5 responses with uniform anchors of 0= normal, 1= slight, 2= mild, 3= moderate, and 4= severe. Total score ranges from 0 to 52, higher score indicating severe conditions. A positive change from baseline indicates worsening. Baseline, Week 52
Secondary Clinical Global Impression of Change (CGI-C) Scale Score The CGI-C scale measures the change in the patient's clinical status from a specific point in time. Using a 7-point scale, ranging from 1 (very much improved) to 7 (very much worse), with a score of 4 indicating no change. Week 52
Secondary Change From Baseline in Progressive Supranuclear Palsy (PSP)-Cognitive Composite Battery Z-Score at Week 52 The PSP cognitive composite battery is used to identify and characterize abnormal cognitive decline in PSP participants. The PSP cognitive composite battery includes 13 sub-tests in total: 11 tests from the RBANS (only the picture naming is excluded), letter number sequencing test, and phonemic fluency test. Three domains are identified: Memory and learning, Visual-Motor function, and Working memory and Executive. A z-score transformation is applied for each component test at each visit, and the final total composite z-score is the average of the three-domain z-scores. A z-score of 0 is equal to the estimated mean adjusted by age and is considered average for this study population. Lower values are indicative of cognitive decline. A negative change from baseline indicates worsening. Baseline, Week 52
Secondary Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Disease Severity (RBANS) Scale at Week 52 The RBANS provides both a total scale score and scores for 5 different cognitive domains. Specifically, the test measures immediate memory, visuospatial/constructional ability, language, attention, and delayed memory. Scores from all subtests are aggregated into a total composite score. RBANS data were age-normed and analyzed as index scores (also referred to as standard scores), which have a mean of 100 and a standard deviation of 15. Higher scores on each sub measure and index indicate better performance. A negative change from baseline indicates worsening. Baseline, Week 52
Secondary Change From Baseline in Progressive Supranuclear Palsy Quality of Life Scale (PSP-QoL) Score The PSP-QoL is a patient-reported outcome measure developed specifically for assessing the health-related quality of life in people living with PSP. It is validated 45-item questionnaire and visual analog scale that is comprised of 2 subscales: physical health state (22 items), which covers mobility, dysarthria, dysphagia, visual disturbances, self-care, and activities of daily living, and mental health state (23 items), which covers emotional, cognitive and social functioning. Items are given a 6-reponse option format (No Problem, Slight Problem, Moderate Problem, Marked Problem, Extreme Problem and Not Applicable). The subscale results are derived by summing the respective items for that subscale and transforming the scores into a range of 0 to 100, the higher the scores indicating a greater impact of the disease on the aspect measured. The PSP-QoL also comprises of a Life Satisfaction rating gauge, which is a visual analog scale with a range of 0 (worst) to 100 (best). Baseline, Week 52
Secondary Change From Baseline in Schwab and England Activities of Daily Living (SEADL) Scale Score at Week 48 The SEADL scale is a means of assessing a person's ability to perform daily activities in terms of speed and independence, with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). A negative change from baseline indicates worsening. Baseline, Week 48
Secondary Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Week 52 The Clinical Global Impression of Severity (CGI-S) Rating evaluates the severity of individual symptoms and treatment response in participants with mental disorders. The CGI-S is a 7-point scale that that requires the clinician to rate the severity of the patient's illness at the time of assessment. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms. Baseline, Week 52
Secondary Change From Baseline in Phonemic Fluency Test Score at Week 48 Phonemic fluency is a sensitive test for assessing frontal lobe dysfunction. Participants are given a letter of the alphabet and asked to name as many words as they can that start with that letter in 1 minute. The score for each trial is auto-calculated as follows: Trial 1: Total number of correct responses for the first letter (range 0 to 40); Trial 2: Total number of correct responses for the second letter (range 0 to 40). The total score from the two trials will be used for analysis (range 0 to 80). More number of words correlates to better phonemic fluency. A negative change from baseline indicates worsening. Baseline, Week 48
Secondary Change From Baseline in Letter-Number Sequencing Test at Week 48 Letter number is a test of working memory which involves ordering a series of up to 8 letters and numbers in which the numbers are repeated back first in order starting with the lowest number, then followed by the letters in alphabetical order. LNS consists of 10 items and each item has 3 trials rated as Incorrect (0) or Correct (1). The LNS total raw score (range 0 to 30) is auto-calculated by summing the 10 individual item scores (range 0 to 3 for each item). Higher number of correct items correlated to better performance and a negative change from baseline indicates worsening. Baseline, Week 48
Secondary Change From Baseline in Color Trails at Week 48 The Color Trails test is a language free version of the Trail Making Test and was developed to allow for broader cross cultural assessment. For Part 1 (color trails test 1), the respondent uses a pencil to rapidly connect circles numbered 1-25 in sequence. For Part 2 (color trails test 2), the respondent rapidly connects number circles in sequence, but alternates between pink and yellow background. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors. Less time indicates better performance. A positive change from baseline indicates worsening. Baseline, Week 48
Secondary Change From Baseline in Montreal Cognitive Assessment (MoCA) Score at Week 48 The MOCA was designed as a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive function, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MOCA range from 0-30, with higher score being better performance. A negative change from baseline indicates worsening. Baseline, Week 48
Secondary Number of Participants With Treatment Emergent Antibodies (Anti-BIIB092) Positive Results in Serum Up to Week 48
Secondary Change From Baseline of Brain Volumes as Determined by MRI at Week 52 A 3 dimension (3D) T1-weighted MRI was performed to estimate brain volumes (e.g., ventricles, whole brain, midbrain, pons, superior cerebellar peduncle, third ventricle, and frontal lobes). Baseline, Week 52
See also
  Status Clinical Trial Phase
Completed NCT00368199 - Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes N/A
Completed NCT02132052 - Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Recruiting NCT04468932 - Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy N/A
Completed NCT04858893 - Application of Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms
Terminated NCT02658916 - Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 Phase 1
Recruiting NCT00139373 - Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Phase 2